Eli Lilly Projects 30% Annual Revenue CAGR to $158.7B and 75% Upside
JNJ•Eli Lilly’s immunology, oncology and neuroscience franchises grew 160%, underpinned by an R&D engine that management says would rank it among the fastest-growing pharma players even without its metabolic business. A three-year model assumes 30% annual revenue CAGR to $158.7 billion and margins easing to 31.3%, yielding a 75% upside target.
1. Revenue Growth Outlook
Analysts model revenue compounding at 30% annually, rising from $72.2 billion in the last twelve months to $158.7 billion in three years. This pacing reflects a step down from the LTM 47.4% growth rate but still underscores broad-based momentum beyond the incretin franchise.
2. Margin Assumptions
The scenario assumes operating margins retreat from 35.0% to 31.3% as short-term peaks give way to longer-run averages. This modest contraction balances strong top-line expansion with conservative expectations on cost structures.
3. Earnings Projection
Under these assumptions, earnings climb from $25.3 billion to roughly $49.7 billion over three years, representing a 97% increase. The bulk of upside stems from this near doubling of profits driven by scalable franchises in immunology, oncology and neuroscience.
4. Valuation Impact
The projection trims the P/E multiple from 38.2x to 34.0x to reflect a slower forward growth profile, reducing the earnings-driven gain by about 11%. Applying 34.0x to $49.7 billion yields a market capitalization near $1.7 trillion and a per-share target around $1,889, implying 75% upside.
